OBJECTIVETo confirm the enhancing effect of excision repair cross complementing rodent repair deficiency gene 2 (ERCC2) on alkylating agents resistance.

METHODSThe authors constructed a pcDNA3-ERCC2 plasmid. The pcDNA3-ERCC2 was transfected into a selected ERCC2 negative human glioma cell line, SKMG-4, using liposome-mediated transfection. After G418 selection, a stable transfected cell line was obtained and tested for cytotoxicity of several alkylating agents.

RESULTSThe stable transfectant was obtained and confirmed by RT-PCR as well as Western blot analysis to be strongly expressing ERCC2 at both mRNA and protein levels. The IC(90) ( micro mol/L) of two alkylating agents, cisplatin and melphalan, increased from 1.0 to 1.75 (75%) and 5.6 to 9.0 (61%), respectively, compared with control cell line.

CONCLUSIONThe present data provided evidences and confirmed the authors' previous results that ERCC2 contributes, at least partially, to alkylating agent resistance in human glioma cell line.

Antineoplastic Agents, Alkylating ; pharmacology ; Cisplatin ; pharmacology ; DNA Helicases ; DNA-Binding Proteins ; Drug Resistance, Neoplasm ; genetics ; Glioma ; Humans ; Melphalan ; pharmacology ; Proteins ; genetics ; Transcription Factors ; Transfection ; Tumor Cells, Cultured ; Xeroderma Pigmentosum Group D Protein